Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases.
OBJECTIVE
Mandated post-marketing drug safety studies require vast databases pooled from multiple administrative data sources which can contain private and proprietary information. We sought to create a method to conduct pooled analyses while keeping information private and allowing for full confounder adjustment.


METHODS
We propose a method based on propensity score (PS) techniques. A set of propensity scores are computed in each data-contributing center and a PS-adjusted analysis is then carried out on a pooled basis. The method is demonstrated in a study of the potentially negative effects of concurrent initiation of clopidogrel and proton pump inhibitors (PPIs) in four cohorts of patients assembled from North American claims data sources. Clinical outcomes were myocardial infarction (MI) hospitalization and hospitalization for revascularization procedure. Success of the method was indicated by equivalent performance of our PS-based method and traditional confounder adjustment. We also implemented and evaluated high-dimensional propensity scores and meta-analytic techniques.


RESULTS
On both a pooled and individual cohort basis, we saw substantially similar point estimates and confidence intervals for studies adjusted by covariates and from privacy-maintaining propensity scores. The pooled, adjusted OR for MI hospitalization was 1.20 (95% confidence interval 1.03, 1.41) with individual variable adjustment and 1.16 (1.00, 1.36) with PS adjustment. The revascularization OR estimates differed by < 1%. Meta-analysis and pooling yielded substantially similar results.


CONCLUSIONS
We observed little difference in point estimates when we employed standard techniques or the proposed privacy-maintaining pooling method. We would recommend the technique in instances where multi-center studies require both privacy and multivariate adjustment.
Rassen
Jeremy A
JA
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. jrassen@post.harvard.edu
Avorn
Jerry
J
Schneeweiss
Sebastian
S
D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077144:Clopidogrel; D003219:Confidentiality; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000139:chemically induced / Q000150:complications; D017891:Pharmacoepidemiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D018907:Privacy; D011358:Product Surveillance, Postmarketing; D057216:Propensity Score; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014600:Utilization Review
D000897:Anti-Ulcer Agents; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine